Amylyx Pharmaceuticals In... (AMLX)
NASDAQ: AMLX
· Real-Time Price · USD
5.14
0.03 (0.59%)
At close: May 01, 2025, 3:59 PM
5.35
3.98%
After-hours: May 01, 2025, 07:13 PM EDT
Company Description
Amylyx Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, engages in developing various therapeutics for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.
The company's product pipeline includes AMX0035, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of amyotrophic lateral sclerosis.
It is also developing AMX0035 for other neurodegenerative diseases.
The company was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Amylyx Pharmaceuticals Inc.
| Country | United States |
| IPO Date | Jan 7, 2022 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 123 |
| CEO | Joshua B. Cohen |
Contact Details
Address: 43 Thorndike Street Cambridge, Massachusetts United States | |
| Website | https://amylyx.com |
Stock Details
| Ticker Symbol | AMLX |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001658551 |
| CUSIP Number | 03237H101 |
| ISIN Number | US03237H1014 |
| Employer ID | 46-4600503 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Joshua B. Cohen | Co-Founder, Co-Chief Executive Officer & Director |
| Justin B. Klee | Co-Founder, Co-Chief Executive Officer & Director |
| Gina M. Mazzariello J.D. | Chief Legal Officer & General Counsel |
| James M. Frates M.B.A. | Chief Financial Officer |
| Dr. Jamie Timmons | Head of Global Medical Strategy & Communications |
| Dr. Machelle Manuel Ph.D. | Vice President & Head of Global Medical Affairs |
| Linda A. Arsenault | Chief Human Resources Officer |
| Lindsey Allen | Head of Investor Relations & Communications |
| Tammy Sarnelli | Global Head of Regulatory Affairs |
| Tom Holmes | Chief Technical Operations Officer |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Apr 24, 2025 | ARS | Filing |
| Apr 24, 2025 | DEFA14A | Filing |
| Apr 24, 2025 | DEF 14A | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Apr 02, 2025 | 4 | Filing |
| Mar 24, 2025 | 4 | Filing |
| Mar 10, 2025 | 4 | Filing |